- Home
- ARQQ vs PRLD Comparison
ARQQ vs PRLD Comparison
Compare ARQQ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQQ | PRLD |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United Kingdom | United States |
| Employees | 91 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 218.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ARQQ | PRLD |
|---|---|---|
| Price | $13.37 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $60.00 | $5.67 |
| AVG Volume (30 Days) | 335.4K | ★ 506.5K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $381.13 | $320.10 |
| Revenue Next Year | $212.00 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $11.52 | $0.75 |
| 52 Week High | $62.00 | $5.54 |
Technical Indicators
Market Signals| Indicator | ARQQ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 50.39 |
| Support Level | $13.04 | $1.09 |
| Resistance Level | $17.75 | $5.43 |
| Average True Range (ATR) | 1.02 | 0.53 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 14.83 | 35.29 |
Price Performance
Historical ComparisonAbout ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.